144 related articles for article (PubMed ID: 15720519)
1. Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs.
Moreau M; Daminet S; Martel-Pelletier J; Fernandes J; Pelletier JP
J Vet Pharmacol Ther; 2005 Feb; 28(1):81-6. PubMed ID: 15720519
[TBL] [Abstract][Full Text] [Related]
2. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial.
Bias P; Buchner A; Klesser B; Laufer S
Am J Gastroenterol; 2004 Apr; 99(4):611-8. PubMed ID: 15089890
[TBL] [Abstract][Full Text] [Related]
3. The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.
Rotondo S; Dell'Elba G; Manarini S; Cerletti C; Evangelista V
Eur J Pharmacol; 2006 Sep; 546(1-3):95-101. PubMed ID: 16920097
[TBL] [Abstract][Full Text] [Related]
4. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.
Vidal C; Gómez-Hernández A; Sánchez-Galán E; González A; Ortega L; Gómez-Gerique JA; Tuñón J; Egido J
J Pharmacol Exp Ther; 2007 Jan; 320(1):108-16. PubMed ID: 17015640
[TBL] [Abstract][Full Text] [Related]
5. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
[TBL] [Abstract][Full Text] [Related]
6. Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow.
Ulbrich H; Soehnlein O; Xie X; Eriksson EE; Lindbom L; Albrecht W; Laufer S; Dannhardt G
Biochem Pharmacol; 2005 Jul; 70(1):30-6. PubMed ID: 15894291
[TBL] [Abstract][Full Text] [Related]
7. Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors.
Boileau C; Martel-Pelletier J; Jouzeau JY; Netter P; Moldovan F; Laufer S; Tries S; Pelletier JP
J Rheumatol; 2002 Jul; 29(7):1446-53. PubMed ID: 12136904
[TBL] [Abstract][Full Text] [Related]
8. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
9. Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats.
Yokota A; Taniguchi M; Takahira Y; Tanaka A; Takeuchi K
J Pharmacol Exp Ther; 2005 Jul; 314(1):302-9. PubMed ID: 15831440
[TBL] [Abstract][Full Text] [Related]
10. Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
Alvaro-Gracia JM
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i21-5. PubMed ID: 14752172
[TBL] [Abstract][Full Text] [Related]
11. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade.
Tavolari S; Bonafè M; Marini M; Ferreri C; Bartolini G; Brighenti E; Manara S; Tomasi V; Laufer S; Guarnieri T
Carcinogenesis; 2008 Feb; 29(2):371-80. PubMed ID: 18033773
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.
Hawkey C; Laine L; Simon T; Beaulieu A; Maldonado-Cocco J; Acevedo E; Shahane A; Quan H; Bolognese J; Mortensen E
Arthritis Rheum; 2000 Feb; 43(2):370-7. PubMed ID: 10693877
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
Coruzzi G; Venturi N; Spaggiari S
Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory effect of licofelone against various inflammatory challenges.
Singh VP; Patil CS; Kulkarni SK
Fundam Clin Pharmacol; 2006 Feb; 20(1):65-71. PubMed ID: 16448396
[TBL] [Abstract][Full Text] [Related]
15. Effects on primary haemostasis of an anti-inflammatory agent with 5-lipoxygenase and cyclooxygenase inhibitory activity.
Hernandez MR; Tonda R; Pedreño J; Salas E; Arderiu G; Pino M; Serradell M; Escolar G
J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):859-65. PubMed ID: 17122671
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
[TBL] [Abstract][Full Text] [Related]
17. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
Michael Hill C; Sindet-Pederson S; Seymour RA; Hawkesford JE; Coulthard P; Lamey PJ; Gerry Cowan C; Wickens M; Jeppsson L; Dean AD; Svensson O
Clin Ther; 2006 Sep; 28(9):1279-95. PubMed ID: 17062301
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice.
Dhir A; Padi SS; Naidu PS; Kulkarni SK
Eur J Pharmacol; 2006 Mar; 535(1-3):192-8. PubMed ID: 16522321
[TBL] [Abstract][Full Text] [Related]
19. Effect of licofelone against NSAIDs-induced gastrointestinal ulceration and inflammation.
Singh VP; Patil CS; Kulkarni SK
Indian J Exp Biol; 2005 Mar; 43(3):247-53. PubMed ID: 15816411
[TBL] [Abstract][Full Text] [Related]
20. COX-LOX inhibition: current evidence for an emerging new therapy.
Skelly MM; Hawkey CJ
Int J Clin Pract; 2003 May; 57(4):301-4. PubMed ID: 12800462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
